Substance / Medication

Sulfabenzamide

Overview

Active Ingredient
sulfabenzamide
RxNorm CUI
37320

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Local oestrogen for vaginal atrophy in postmenopausal women.
Lethaby Anne, Ayeleke Reuben Olugbenga, Roberts Helen · Cochrane Database Syst Rev · 2016
PMID: 27577677Meta-AnalysisFull text (PMC)
Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J, Lethaby A, Kennedy R · Cochrane Database Syst Rev · 2006
PMID: 17054136Meta-Analysis
Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review.
Van Kessel Katherine, Assefi Nassim, Marrazzo Jeanne et al. · Obstet Gynecol Surv · 2003
PMID: 12719677Meta-Analysis
Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J, Lethaby A, Kennedy R · Cochrane Database Syst Rev · 2003
PMID: 14583935Meta-Analysis
Efficacy and safety of three plant extracts based formulations of vagitories in the treatment of vaginitis: a randomized controlled trial.
Durić Kemal, Kovčić Hadžiabdić Selma, Durić Mahira et al. · Med Glas (Zenica) · 2021
PMID: 33269580RCT
Synthesis of sulfamethoxazole and sulfabenzamide metal complexes; evaluation of their antibacterial activity.
Rostamizadeh Shahnaz, Daneshfar Zahra, Moghimi Hamid · Eur J Med Chem · 2019
PMID: 30928708Other
Electron ionization mass spectra of alkylated sulfabenzamides.
Todua Nino G, Tretyakov Kirill V, Borisov Roman S et al. · Rapid Commun Mass Spectrom · 2011
PMID: 21337636OtherFull text (PMC)
A systematic study on hydrogen bond interactions in sulfabenzamide: DFT calculations of the N-14, O-17, and H-2 NQR parameters.
Nozad Ahmad G, Najafi Hamidreza, Meftah Sakineh et al. · Biophys Chem · 2009
PMID: 19028005Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sulfabenzamide (substance)
SNOMED CT
371427008
UMLS CUI
C0075504
RxNorm CUI
37320

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.